GURU.Markets stock price, segment price, and overall market index valuation
The company's share price AN2 Therapeutics Inc.
AN2 Therapeutics is a biopharmaceutical company focused on treating infectious diseases. Its stock price reflects the progress of its lead drug's clinical trials. The chart tells a story of the risks and hopes associated with developing new antibiotics.
Share prices of companies in the market segment - Pharma infections
AN2 Therapeutics is a biopharmaceutical company developing novel treatments for rare infectious diseases with high unmet medical needs. We've categorized it as a Pharmaceutical: Infections company. The chart below shows how investors value companies in this niche.
Broad Market Index - GURU.Markets
AN2 Therapeutics is a biopharmaceutical company developing treatments for rare infectious diseases with high unmet needs. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ANTX - Daily change in the company's share price AN2 Therapeutics Inc.
For AN2 Therapeutics, Inc., an antibiotic developer, daily price change is a measure of enormous volatility. This metric reflects extreme sensitivity to clinical trial data and is key to assessing biotech risks.
Daily change in the price of a set of shares in a market segment - Pharma infections
AN2 Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with ANTX, which focuses on infectious disease treatments, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
AN2 Therapeutics is a pharmaceutical company specializing in infectious diseases. Its shares are driven by news about new drug developments. This dynamic, specific to the pharmaceutical industry, creates fluctuations that contribute to overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization AN2 Therapeutics Inc.
AN2 Therapeutics, Inc.'s year-over-year performance is a story about the development of a new antibiotic for the treatment of tuberculosis. Its 12-month market cap is entirely dependent on clinical trial data. The success of its drug could be a significant milestone in the fight against this global threat, but antibiotic development is a risky and complex process.
Annual dynamics of market capitalization of the market segment - Pharma infections
AN2, as an early-stage biotech company, is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its anti-infective drugs. Its stock price will reflect investors' speculative belief in the potential of its developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
AN2 Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization AN2 Therapeutics Inc.
AN2 Therapeutics is a biopharmaceutical company fighting infectious diseases. Its monthly performance is entirely dependent on the results of its clinical trials. News of progress with its lead tuberculosis drug is the main driver of its value.
Monthly dynamics of market capitalization of the market segment - Pharma infections
AN2 Therapeutics develops new treatments for infectious diseases, particularly tuberculosis. This segment of the pharmaceutical industry has enormous social significance but is often underfunded. The chart below shows how investors assessed the commercial prospects and risks of companies tackling global infectious threats.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
AN2 Therapeutics is a clinical-stage biotech company focused on treating infectious diseases. Its stock is a classic biotech story: its performance is disconnected from the market and depends entirely on clinical trial results and scientific news.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization AN2 Therapeutics Inc.
AN2 Therapeutics is a biotech company developing drugs to treat rare infectious diseases. Its weekly stock price is volatile, driven by news about clinical trials and the growing need for new antibiotics due to bacterial resistance.
Weekly dynamics of market capitalization of the market segment - Pharma infections
AN2 Therapeutics is a biotech company developing drugs to treat rare infectious diseases. Its weekly stock price is volatile, driven by news about clinical trials and the growing need for new antibiotics due to bacterial resistance.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of AN2, a biotech company, live in a world of their own. Their performance is driven by clinical trial data. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
ANTX - Market capitalization of the company AN2 Therapeutics Inc.
The AN2 Therapeutics market capitalization chart tells a focused story about the development of a new antibiotic for the treatment of a rare but difficult-to-treat lung disease. Its dynamics reflect all the risks and hopes associated with bringing a new antibacterial drug to market in a challenging market environment for this class of drugs.
ANTX - Share of the company's market capitalization AN2 Therapeutics Inc. within the market segment - Pharma infections
AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of rare infectious diseases. Its market capitalization reflects the potential of its lead candidate. The chart below shows the valuation volatility dependent on clinical trial results.
Market capitalization of the market segment - Pharma infections
AN2 Therapeutics develops drugs to treat rare infectious diseases with high unmet needs. The chart below shows the total market capitalization of the infectious pharmaceuticals sector. It illustrates the importance of developing drugs for orphan diseases, where the market is small but the need is critical.
Market capitalization of all companies included in a broad market index - GURU.Markets
This graph represents the fight against tuberculosis. AN2 Therapeutics is developing a new antibiotic to treat this deadly disease. Its pipeline reflects progress in clinical trials and the hope of creating a new weapon against a disease that is becoming increasingly resistant to older drugs.
Book value capitalization of the company, segment and market as a whole
ANTX - Book value capitalization of the company AN2 Therapeutics Inc.
AN2 Therapeutics' book value is its financial reserves and the rights to develop an oral antibiotic for the treatment of non-tuberculous mycobacterial lung diseases. This represents focused scientific capital. The chart shows how the biotech company manages its budget for late-stage clinical trials of its key drug.
ANTX - Share of the company's book capitalization AN2 Therapeutics Inc. within the market segment - Pharma infections
AN2 Therapeutics is a biotech company developing new treatments for infectious diseases. Its assets are intellectual property. The chart shows a minimal share of physical assets, which is typical for a clinical-stage company.
Market segment balance sheet capitalization - Pharma infections
Antibiotic development, as the BCap_Ges chart for biotech shows, is a science-intensive industry. AN2 Therapeutics operates in this environment, where capital is invested in clinical trials to combat resistant infections rather than in building factories.
Book value of all companies included in the broad market index - GURU.Markets
AN2 Therapeutics' assets are capital invested in developing a new antibiotic for the treatment of chronic lung infections. This book value provides the financial foundation that allows the company to advance its drug through costly trials to become a viable, tangible treatment.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - AN2 Therapeutics Inc.
AN2 Therapeutics develops drugs to treat infectious diseases. This is an important yet often undervalued area of pharmaceuticals. The company's market capitalization is a measure of its developments in this niche. The MvsBCap chart will reflect progress in clinical trials and the threat posed by emerging infections.
Market to book capitalization ratio in a market segment - Pharma infections
AN2 Therapeutics is a biopharmaceutical company developing drugs to treat infectious diseases. Its value is based on the potential of its clinical development pipeline. The chart shows how investors assess its chances of success in the fight against rare diseases.
Market to book capitalization ratio for the market as a whole
AN2 Therapeutics develops new treatments for infectious diseases, particularly tuberculosis. This is a socially significant but complex field. The company's market valuation reflects the potential of its drugs and the demand for new antibiotics, not its current tangible assets.
Debts of the company, segment and market as a whole
ANTX - Company debts AN2 Therapeutics Inc.
AN2 Therapeutics, a clinical-stage biopharmaceutical company focused on treating infectious diseases, is devoting all its capital to R&D. Developing new antibiotics is a critical yet complex task. This chart shows how the company is funding its research in an effort to address growing drug resistance.
Market segment debts - Pharma infections
AN2 Therapeutics is a clinical-stage biopharmaceutical company developing treatments for chronic infectious diseases. Funding long-term clinical trials for antibiotics is challenging. This chart shows how the company is raising capital to address this important but commercially challenging medical problem.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio AN2 Therapeutics Inc.
AN2 Therapeutics fights infectious diseases by developing new antibiotics. This chart shows how dependent the company is on external funding. While its work is crucial in the face of growing bacterial drug resistance, its high debt creates risks if clinical trials are delayed or the drug fails to receive regulatory approval.
Market segment debt to market segment book capitalization - Pharma infections
AN2 Therapeutics is a clinical-stage biopharmaceutical company developing treatments for chronic infectious diseases. The chart shows the sector's debt load, helping to understand how the company finances its lengthy and expensive clinical trials in its quest to bring new antibiotics and anti-infective drugs to market.
Debt to book value of all companies in the market
AN2 Therapeutics is a biopharmaceutical company developing treatments for rare infectious diseases with high unmet needs. The overall debt level, shown in this chart, impacts the availability of financing. For niche developments requiring significant investment, capital market conditions play a key role.
P/E of the company, segment and market as a whole
P/E - AN2 Therapeutics Inc.
For AN2 Therapeutics, a company fighting infectious diseases, this chart shows investor expectations for its antibacterial drugs. The trend reflects the market's belief that the company will be able to offer a solution to combat drug-resistant bacteria, a global public health threat.
P/E of the market segment - Pharma infections
This chart shows the average price-to-earnings ratio for the pharmaceutical industry, where AN2 Therapeutics fights infections. This ratio serves as a benchmark for assessing the premium the market is willing to pay for the company's drugs aimed at addressing the problem of growing bacterial resistance to antibiotics.
P/E of the market as a whole
AN2 Therapeutics is a biopharmaceutical company developing drugs to treat rare infectious diseases with high unmet needs. Its lead candidate targets non-tuberculous mycobacterial infections. This chart shows biotech sentiment. It helps understand how the market views the commercial potential of rare disease drugs and AN2's chances of success.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company AN2 Therapeutics Inc.
AN2 Therapeutics is a biopharmaceutical company specializing in the development of drugs to treat infectious diseases where there is a critical need for new treatments. Its future depends on the success of clinical trials. This chart shows analysts' confidence in the commercial potential of its lead antibiotic candidate.
%20P%2FE%20AN2%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-AN2-Therapeutics-Inc.&v=1772648209274 "Chart of the company's future (projected) P/E AN2 Therapeutics Inc.")
Future (projected) P/E of the market segment - Pharma infections
AN2 Therapeutics is a biopharmaceutical company focused on developing treatments for rare infectious diseases with high unmet needs. This chart shows how its future revenue expectations compare to the industry average, reflecting the market potential of its niche developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-infections&v=1772648209308 "Future (projected) P/E graph of the market segment - Pharma infections")
Future (projected) P/E of the market as a whole
AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on treating infectious diseases. Its valuation depends on the success of its developments and the overall investment climate, as illustrated by this chart. During periods when investors are more willing to take risks, companies like AN2 have an easier time raising funding for their research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772648209351 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit AN2 Therapeutics Inc.
AN2 Therapeutics, Inc. is a biotechnology company developing drugs to treat rare infectious diseases. Its financial activities are focused on clinical trials. This chart shows the volume of investments in the development of new antibiotics, a critical yet complex task in modern medicine.
Profit of companies in the market segment - Pharma infections
AN2 Therapeutics is a biopharmaceutical company developing drugs to treat rare infectious diseases with high unmet needs. Its focus is on non-tuberculous mycobacterioses. This chart shows the overall profitability of the pharmaceutical industry, where the development of drugs for orphan (rare) diseases can be commercially successful due to high prices and a lack of competition.
Overall market profit
AN2 Therapeutics is a biotech company developing drugs to treat infectious diseases. While the need for new antibiotics is enormous, commercial success depends on reimbursement models. The overall economic situation, reflected in the graph, impacts the budgets of healthcare systems responsible for such procurement.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company AN2 Therapeutics Inc.
AN2 Therapeutics is a biopharmaceutical company focused on developing treatments for rare infectious diseases with high unmet needs. This chart shows how analysts assess the commercial potential of its niche drugs, which depends on the success of clinical trials.
%20profit%20of%20the%20company%20AN2%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-AN2-Therapeutics-Inc.&v=1772648209467 "Graph of future (projected) profit of the company AN2 Therapeutics Inc.")
Future (predicted) profit of companies in the market segment - Pharma infections
AN2 Therapeutics is a biopharmaceutical company focused on developing drugs to treat rare infectious diseases with high unmet needs. Its lead program targets non-tuberculous mycobacteria. This chart shows profitability projections for the pharmaceutical sector, providing context for assessing the potential of companies operating in the orphan disease niche.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-infections&v=1772648209536 "Graph of future (predicted) profits of companies in a market segment - Pharma infections")
Future (predicted) profit of the market as a whole
AN2 Therapeutics is a biopharmaceutical company focused on developing treatments for infectious diseases. Despite the urgent need, funding for these developments competes with other areas of medicine. This chart, reflecting overall market sentiment, influences investor willingness to invest in less hyped but critically important areas of biotech.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772648209605 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - AN2 Therapeutics Inc.
AN2 Therapeutics develops drugs to treat infectious diseases. For a biotech company, this chart shows its potential. Market value relative to revenue reflects the urgency of the problem and the belief that its drug will be a key tool in the fight against disease.
P/S market segment - Pharma infections
AN2 Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for rare infectious diseases with high unmet needs. This chart shows the average revenue estimate in the biotech sector. It helps understand how investors assess the potential revenue from the company's niche drugs in their target markets.
P/S of the market as a whole
AN2 Therapeutics is a biopharmaceutical company focused on developing treatments for rare infectious diseases with high unmet needs. Their success depends on clinical data. This chart provides a general revenue metric that can be used to assess how the market values biotech companies working to solve complex infectious diseases.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company AN2 Therapeutics Inc.
AN2 Therapeutics is a biopharmaceutical company focused on developing treatments for rare infectious diseases with high unmet needs. This graph reflects market expectations for its lead drug candidate. This estimate is dependent on the success of clinical trials and the potential to offer a solution for patients with limited treatment options.
%20P%2FS%20AN2%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-AN2-Therapeutics-Inc.&v=1772648209677 "The graph of the company's future (projected) P/S AN2 Therapeutics Inc.")
Future (projected) P/S of the market segment - Pharma infections
AN2 Therapeutics is a clinical-stage biopharmaceutical company developing novel treatments for rare infectious diseases with high unmet needs. This chart shows how the market values its pipeline compared to the infectious disease-focused pharmaceutical sector.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20infections&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-infections&v=1772648209702 "Future (projected) P/S market segment graph - Pharma infections")
Future (projected) P/S of the market as a whole
AN2 Therapeutics is a clinical-stage biopharmaceutical company specializing in the treatment of infectious diseases. This chart, reflecting the overall investment climate in the biotech sector, is important for the company. Market optimism facilitates raising the funding needed to bring new antibiotics to market and conduct further expensive research.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772648209752 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales AN2 Therapeutics Inc.
AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on developing drugs to treat rare infectious diseases. This chart shows its funding streams, which currently consist of grants and research funding. It illustrates investments in the fight against diseases for which there are few or no treatment options.
Sales of companies in the market segment - Pharma infections
AN2 Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for rare infectious diseases with high unmet needs. Its business is segmented by development programs, the key one being a drug for the treatment of tuberculosis. This chart reflects the cash flows associated with this core business.
Overall market sales
AN2 Therapeutics, Inc. is a pharmaceutical company developing new treatments for infectious diseases with high unmet needs. Its focus on rare but serious infections means that demand for its drugs will be driven by medical need rather than general economic conditions. It is an example of a socially responsible business.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company AN2 Therapeutics Inc.
AN2 Therapeutics is a biopharmaceutical company focused on developing treatments for rare infectious diseases with high unmet needs. Its future sales forecast is based on the expected commercial success of its lead candidate for the treatment of non-tuberculous mycobacterial pulmonary infection.
%20sales%20of%20the%20company%20AN2%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-AN2-Therapeutics-Inc.&v=1772648209804 "Schedule of future (projected) sales of the company AN2 Therapeutics Inc.")
Future (projected) sales of companies in the market segment - Pharma infections
AN2 Therapeutics is a biopharmaceutical company developing new treatments for rare infectious diseases with high unmet needs. This chart shows expectations for the entire infectious diseases sector. It helps assess analysts' forecasts for demand for innovative antibiotics and antimicrobials.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-infections&v=1772648209828 "Schedule of future (projected) sales of companies in the market segment - Pharma infections")
Future (projected) sales of the market as a whole
AN2 Therapeutics, a biotech company fighting infectious diseases, depends on funding for research and development. This chart of total sales forecasts reflects the overall state of financial markets, which determines the availability of capital for companies working on global health issues.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772648209839 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality AN2 Therapeutics Inc.
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare infectious diseases with high unmet needs. This chart reflects its financial position, where significant investments in research and development are key to the development of future commercially successful drugs.
Market segment marginality - Pharma infections
AN2 Therapeutics is a biopharmaceutical company developing drugs to treat rare infectious diseases. Focusing on niche markets can provide a cost advantage, but requires effective clinical trials. The chart shows how profitable their business model is compared to pharmaceutical giants.
Market marginality as a whole
AN2 Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for rare infectious diseases with high unmet needs. Its success depends on the results of clinical trials. This graph shows average profitability, but for ANTX, the ability to offer treatments for orphan diseases could lead to significant commercial success.
Employees in the company, segment and market as a whole
Number of employees in the company AN2 Therapeutics Inc.
AN2 Therapeutics is a biotech company focused on developing drugs for rare infectious diseases. This chart shows a small but dedicated team of scientists. The size of this team reflects the company's strategy of targeting niche areas with unmet medical needs.
Share of the company's employees AN2 Therapeutics Inc. within the market segment - Pharma infections
AN2 Therapeutics develops new treatments for infectious diseases, with a particular focus on tuberculosis. Combating such global threats requires a dedicated team of scientists. This chart shows their human resource commitment to this critically important, yet often underfunded, area of medicine.
Number of employees in the market segment - Pharma infections
AN2 Therapeutics is a biopharmaceutical company developing drugs to treat rare infectious diseases. This chart reflects employment in this sector. The growing number of microbiologists and clinicians highlights the global problem of antibiotic resistance and the need for new treatments, creating an important niche for AN2's development.
Number of employees in the market as a whole
AN2 Therapeutics is a biopharmaceutical company fighting infectious diseases. Demand for new antibiotics is enormous due to growing resistance. This chart shows the overall economics, but for AN2, gaining regulatory approval and offering a solution to a global health problem is more important.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company AN2 Therapeutics Inc. (ANTX)
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on treating infectious diseases. This chart likely shows a high market capitalization per employee. This reflects the market valuation of the potential of its lead drug, not current revenue or assets.
%20of%20the%20company%20AN2%20Therapeutics%20Inc.%20(ANTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-AN2-Therapeutics-Inc.-ANTX&v=1772648210023 "Chart of market capitalization per employee (in thousands of dollars) of the company AN2 Therapeutics Inc. (ANTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma infections
AN2 Therapeutics, Inc. is a biopharmaceutical company developing drugs to treat rare infectious diseases. In this niche area of medicine, the company's per-employee price reflects the market's assessment of its scientific potential and the exclusivity of its developments. This demonstrates the extent to which investors believe in its ability to address unmet medical needs.
%20by%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-infections&v=1772648210030 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma infections")
Market capitalization per employee (in thousands of dollars) for the overall market
AN2 Therapeutics, Inc. is a biotechnology company developing novel treatments for infectious diseases with high unmet needs. This chart shows how the market values the scientific team working to address serious public health challenges such as tuberculosis.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772648210050 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company AN2 Therapeutics Inc. (ANTX)
AN2 Therapeutics is a clinical-stage biopharmaceutical company specializing in developing drugs for rare infectious diseases with high unmet medical needs (e.g., non-tuberculous mycobacteriosis). This negative graph shows R&D intensity, measuring how much capital is invested in each scientist to address these complex infectious diseases.
%20Chart%20AN2%20Therapeutics%20Inc.%20(ANTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-AN2-Therapeutics-Inc.-ANTX&v=1772648210054 "Company Profit Per Employee (in thousands of dollars) Chart AN2 Therapeutics Inc. (ANTX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma infections
AN2 Therapeutics is a biopharmaceutical company focused on treating rare infectious diseases. Developing drugs for niche markets requires exceptional performance from its research teams. This metric demonstrates how productive they are in developing valuable medical solutions and serves as a benchmark for comparison with other players in the sector.
%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-infections&v=1772648210125 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma infections")
Profit per employee (in thousands of dollars) for the market as a whole
AN2 Therapeutics (ANTX) is a biotech company developing new treatments for infectious diseases (such as tuberculosis). It's a clinical-stage R&D company. Negative profit per employee is the norm. The graph shows the "cost" of a team of scientists working on this socially significant but complex problem.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772648210162 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee AN2 Therapeutics Inc. (ANTX)
AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on treating infectious diseases. Its revenue is currently likely nonexistent. This graph will eventually reveal whether its lead tuberculosis drug will be commercially successful.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-AN2-Therapeutics-Inc.-ANTX&v=1772648210190 "Sales chart per company employee AN2 Therapeutics Inc. (ANTX)")
Sales per employee in the market segment - Pharma infections
AN2 Therapeutics is a biopharmaceutical company developing drugs to treat rare infectious diseases, specifically non-tuberculous mycobacteriosis of the lungs. This chart compares their revenue per employee (R&D) to the industry average, reflecting the productivity of their research in this niche area.
Sales per employee for the market as a whole
AN2 Therapeutics (ANTX) is a biotech company focused on treating rare infectious diseases (e.g., non-tuberculous mycobacteriosis). These diseases are in the clinical stage. The company has no commercial sales revenue. This graph will reflect $0, as all employees (scientists) are focused on clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company AN2 Therapeutics Inc. (ANTX)
AN2 Therapeutics (ANTX) is a biotech company developing drugs to treat rare infectious diseases (such as non-tuberculous mycobacteriosis). This is a niche market where conducting trials is difficult. This chart shows the number of investors who doubt the drug's market potential or its chances of approval.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-AN2-Therapeutics-Inc.-ANTX&v=1772648210241 "Short Shares Chart for the Company AN2 Therapeutics Inc. (ANTX)")
Shares shorted by market segment - Pharma infections
AN2 Therapeutics is a biotech company specializing in developing new treatments for rare infectious diseases, specifically non-tuberculous mycobacteriosis. This chart shows bets against the "anti-infectious" biotech sector, reflecting investor concerns about the market size for these rare diseases.
Shares shorted by the overall market
AN2 Therapeutics is a biotech focused on treating tuberculosis. This chart illustrates the overall market pessimism. Despite the social importance of the task, panicked investors may avoid biotechs operating in markets where effective demand (often in developing countries) is low and the R&D cycle is long.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator AN2 Therapeutics Inc. (ANTX)
AN2 Therapeutics is a biotech company developing new treatments for infectious diseases, specifically non-tuberculous mycobacteriosis. This chart tracks volatility associated with trial news, showing "overheated" (above 70) on positive data or "oversold" (below 30) on news of trial pauses.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-AN2-Therapeutics-Inc.-ANTX&v=1772648210259 "RSI 14 indicator chart for the company's stock AN2 Therapeutics Inc. (ANTX)")
RSI 14 Market Segment - Pharma infections
AN2 Therapeutics is a biopharmaceutical company focused on treating difficult-to-treat infectious diseases. Its lead drug is being developed to combat non-tuberculous mycobacterial lung infections. This chart measures the overall momentum in the infectious disease biotech sector. It helps separate ANTX's performance from the general industry hype.
RSI 14 for the overall market
AN2 Therapeutics (ANTX) is a biotech company. Like everything in its sector, it's critically dependent on this curve. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ANTX (AN2 Therapeutics Inc.)
AN2 Therapeutics is a biotech company developing an oral drug for the treatment of hard-to-treat tuberculosis. This chart shows the average target price. Analysts' estimates are based on clinical data and the drug's market potential for addressing this global unmet medical need.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ANTX-AN2-Therapeutics-Inc.&v=1772648210342 "A chart showing analyst consensus forecasts for the expected stock price. ANTX (AN2 Therapeutics Inc.)")
The difference between the consensus estimate and the actual stock price ANTX (AN2 Therapeutics Inc.)
AN2 Therapeutics is a biotech company focused on developing drugs to treat rare infectious diseases, primarily tuberculosis. This chart shows the upside and downside potential analysts see for the stock. It measures the gap between the price and forecast, reflecting their belief in this important but complex R&D market.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ANTX-AN2-Therapeutics-Inc.&v=1772648210376 "A chart showing the difference between the consensus forecast and the actual stock price. ANTX (AN2 Therapeutics Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma infections
AN2 Therapeutics is a biotech company focused on developing new treatments for rare infectious diseases with high unmet needs. This chart shows analysts' overall expectations for the pharmaceutical sector, reflecting whether experts believe R&D success in this niche is possible.
Analysts' consensus forecast for the overall market share price
AN2 Therapeutics is a biotech company specializing in developing drugs to treat rare, difficult-to-treat infectious diseases, particularly tuberculosis. This chart shows the company's overall risk appetite. For AN2, which operates in the "defensive" sector (infections need to be treated), overall optimism is important for funding R&D and bringing its drugs to market.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index AN2 Therapeutics Inc.
AN2 Therapeutics is a hunter of neglected diseases. It's a biotech company whose specialty is R&D for treatments for neglected infections, primarily non-tuberculous mycobacteriosis of the lungs. This chart is a pure indicator of their R&D. Its dynamics depend entirely on their (very risky) clinical trial data.
AKIMA Market Segment Index - Pharma infections
AN2 Therapeutics (ANTX) is a biopharmaceutical company specializing in developing treatments for rare infectious diseases. Their lead drug targets non-tuberculous mycobacterial lung infections. The chart shows the average index for the segment, helping investors assess how ANTX's risks in this niche compare to the industry average.
The AKIM Index for the overall market
AN2 Therapeutics is a biopharmaceutical company developing treatments for rare and chronic infectious lung diseases. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which faced the halt of a key trial, compares to overall economic trends.
